"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 5 | 0 | 5 |
| 1997 | 3 | 2 | 5 |
| 1998 | 4 | 2 | 6 |
| 1999 | 6 | 0 | 6 |
| 2000 | 3 | 4 | 7 |
| 2001 | 1 | 1 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 7 | 10 |
| 2004 | 7 | 8 | 15 |
| 2005 | 10 | 5 | 15 |
| 2006 | 6 | 4 | 10 |
| 2007 | 9 | 9 | 18 |
| 2008 | 5 | 5 | 10 |
| 2009 | 5 | 4 | 9 |
| 2010 | 7 | 6 | 13 |
| 2011 | 2 | 3 | 5 |
| 2012 | 12 | 10 | 22 |
| 2013 | 12 | 10 | 22 |
| 2014 | 4 | 9 | 13 |
| 2015 | 9 | 4 | 13 |
| 2016 | 5 | 10 | 15 |
| 2017 | 12 | 3 | 15 |
| 2018 | 5 | 1 | 6 |
| 2019 | 6 | 5 | 11 |
| 2020 | 8 | 5 | 13 |
| 2021 | 8 | 8 | 16 |
| 2022 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
A viewpoint describing the American Society of Transplantation rationale to conduct a comprehensive patient survey assessing unmet immunosuppressive therapy needs. Clin Transplant. 2023 03; 37(3):e14876.
-
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology (Oxford). 2022 10 06; 61(10):4155-4162.
-
Immunosuppressive regimens in porcine transplantation models. Transplant Rev (Orlando). 2022 12; 36(4):100725.
-
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 11; 81(11):1541-1548.
-
Nanotherapeutics in transplantation: How do we get to clinical implementation? Am J Transplant. 2022 05; 22(5):1293-1298.
-
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
-
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 01; 74(1):112-123.
-
Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading? Ren Fail. 2021 Dec; 43(1):273-280.
-
Impact of kidney transplantation on functional status. Ann Med. 2021 12; 53(1):1302-1308.
-
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.